Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 05338F306 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
| T. Rowe Price Investment Management, Inc. 13G/A Amendment 1 | 0% |
8/14/2026
Event 6/30/2026
|
|
|
Caligan Partners LP
13G/A
Amendment 3
|
5.9% |
8/14/2026
Event 6/30/2026
|
|
| Caligan Partners LP | 5.9% | ||
| David Johnson | 5.9% | ||
|
RA Capital Management, L.P.
13G/A
Amendment 5
|
6.3% |
8/14/2026
Event 6/30/2026
|
|
| RA Capital Management, L.P. | 6.3% | ||
| Peter Kolchinsky | 6.3% | ||
| Rajeev Shah | 6.3% | ||
| RA Capital Healthcare Fund, L.P. | 6.3% | ||
|
Deep Track Capital, LP
13G/A
Amendment 1
|
6.9% |
8/14/2026
Event 6/30/2026
|
|
| Deep Track Capital, LP | 6.9% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 6.9% | ||
| David Kroin | 6.9% | ||
|
Nantahala Capital Management, LLC
13G/A
Amendment 2
|
3.5% |
8/14/2026
Event 6/30/2026
|
|
| Nantahala Capital Management, LLC | 3.5% | ||
| Wilmot B. Harkey | 3.5% | ||
| Daniel Mack | 3.5% | ||
|
Biotechnology Value Fund L P
13G/A
Amendment 5
|
5.3% |
8/14/2026
Event 6/30/2026
|
|
| Biotechnology Value Fund L P | 2.8% | ||
| BVF I GP LLC | 2.8% | ||
| Biotechnology Value Fund II LP | 2.1% | ||
| BVF II GP LLC | 2.1% | ||
| Biotechnology Value Trading Fund OS LP | 0.4% | ||
| BVF Partners OS Ltd. | 0.4% | ||
| BVF GP Holdings LLC | 4.8% | ||
| BVF Partners L P/IL | 5.3% | ||
| BVF Inc/IL | 5.3% | ||
| Lampert Mark N | 5.3% | ||
|
Avoro Capital Advisors LLC
13G/A
Amendment 1
|
4.4% |
8/14/2026
Event 6/30/2026
|
|
| Avoro Capital Advisors LLC | 4.4% | ||
| Behzad Aghazadeh | 4.4% | ||
|
Affinity Asset Advisors, LLC
13G/A
Amendment 4
|
5.5% |
8/13/2026
Event 6/30/2026
|
|
| Affinity Asset Advisors, LLC | 5.5% | ||
| Michael Cho | 5.5% | ||
|
FMR LLC
13G/A
Amendment 4
|
10.8% |
8/7/2026
Event 7/31/2026
|
|
| FMR LLC | 10.8% | ||
| Abigail P. Johnson | 10.8% | ||
| State Street Corp 13G | 5.5% |
8/7/2026
Event 6/30/2026
|
|
|
FMR LLC
13G/A
Amendment 3
|
9.7% |
8/6/2026
Event 6/30/2026
|
|
| FMR LLC | 9.7% | ||
| Abigail P. Johnson | 9.7% | ||
| BlackRock, Inc. 13G | 6.5% |
7/27/2026
Event 6/30/2026
|
|
|
Millennium Management LLC
13G/A
Amendment 1
|
0% |
7/6/2026
Event 6/30/2026
|
|
| Millennium Management LLC | 0% | ||
| Millennium Group Management LLC | 0% | ||
| Israel A. Englander | 0% | ||
|
Commodore Capital LP
13G
|
9.9% |
6/18/2026
Event 6/11/2026
|
|
| Commodore Capital LP | 9.9% | ||
| Commodore Capital Master LP | 9.9% | ||
| Robert Egen Atkinson | 9.9% | ||
| Michael Kramarz | 9.9% | ||
|
FMR LLC
13G/A
Amendment 2
|
6.1% |
6/5/2026
Event 5/29/2026
|
|
| FMR LLC | 6.1% | ||
| Abigail P. Johnson | 6.1% | ||
|
Deep Track Capital, LP
13G
|
5.8% |
5/29/2026
Event 5/22/2026
|
|
| Deep Track Capital, LP | 5.8% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 5.8% | ||
| David Kroin | 5.8% | ||
|
Point72 Asset Management, L.P.
13G
|
5.2% |
5/26/2026
Event 5/22/2026
|
|
| Point72 Asset Management, L.P. | 5.2% | ||
| Point72 Capital Advisors, Inc. | 5.2% | ||
| Steven A. Cohen | 5.2% | ||
| T. Rowe Price Investment Management, Inc. 13G | 9.5% |
5/15/2026
Event 3/31/2026
|
|
|
Caligan Partners LP
13G/A
Amendment 2
|
7.2% |
5/15/2026
Event 3/31/2026
|
|
| Caligan Partners LP | 7.2% | ||
| David Johnson | 7.2% | ||
|
RA Capital Management, L.P.
13G/A
Amendment 4
|
9.9% |
5/15/2026
Event 3/31/2026
|
|
| RA Capital Management, L.P. | 9.9% | ||
| Peter Kolchinsky | 9.9% | ||
| Rajeev Shah | 9.9% | ||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||
| OrbiMed Advisors LLC 13G/A Amendment 3 | 2.1% |
5/15/2026
Event 3/31/2026
|
|
|
Logos Global Management LP
13G/A
Amendment 1
|
3.2% |
5/15/2026
Event 3/31/2026
|
|
| Logos Global Management LP | 3.2% | ||
| Logos Global Management GP LLC | 3.2% | ||
| Logos Global Master Fund LP | 3.2% | ||
| Logos GP LLC | 3.2% | ||
| Arsani William | 3.2% | ||
|
Biotechnology Value Fund L P
13G/A
Amendment 4
|
10.0% |
5/15/2026
Event 3/31/2026
|
|
| Biotechnology Value Fund L P | 5.4% | ||
| BVF I GP LLC | 5.4% | ||
| Biotechnology Value Fund II LP | 4.0% | ||
| BVF II GP LLC | 4.0% | ||
| Biotechnology Value Trading Fund OS LP | 0.6% | ||
| BVF Partners OS Ltd. | 0.6% | ||
| BVF GP Holdings LLC | 9.3% | ||
| BVF Partners L P/IL | 10.0% | ||
| BVF Inc/IL | 10.0% | ||
| Lampert Mark N | 10.0% | ||
|
Avoro Capital Advisors LLC
13G
|
5.8% |
5/15/2026
Event 3/31/2026
|
|
| Avoro Capital Advisors LLC | 5.8% | ||
| Behzad Aghazadeh | 5.8% | ||
|
Affinity Asset Advisors, LLC
13G/A
Amendment 3
|
5.5% |
5/14/2026
Event 3/31/2026
|
|
| Affinity Asset Advisors, LLC | 5.5% | ||
| Michael Cho | 5.5% | ||
|
TCG Crossover GP II, LLC
13G
|
7.9% |
5/12/2026
Event 5/5/2026
|
|
| TCG Crossover GP II, LLC | 7.9% | ||
| TCG Crossover Fund II, L.P. | 7.9% | ||
| Chen Yu | 7.9% | ||
|
FMR LLC
13G/A
Amendment 1
|
12.6% |
5/6/2026
Event 3/31/2026
|
|
| FMR LLC | 12.6% | ||
| Abigail P. Johnson | 12.6% | ||
|
Logos Global Management LP
13G
|
5.6% |
4/1/2026
Event 3/26/2026
|
|
| Logos Global Management LP | 5.6% | ||
| Logos Global Management GP LLC | 5.6% | ||
| Logos Global Master Fund LP | 5.6% | ||
| Logos GP LLC | 5.6% | ||
| Arsani William | 5.6% | ||
|
FMR LLC
13G
|
11.5% |
3/6/2026
Event 2/27/2026
|
|
| FMR LLC | 11.5% | ||
| Abigail P. Johnson | 11.5% | ||
|
Millennium Management LLC
13G
|
5.0% |
2/24/2026
Event 2/17/2026
|
|
| Millennium Management LLC | 5.0% | ||
| Millennium Group Management LLC | 5.0% | ||
| Israel A. Englander | 5.0% | ||
|
Caligan Partners LP
13G/A
Amendment 1
|
4.9% |
2/17/2026
Event 12/31/2025
|
|
| Caligan Partners LP | 4.9% | ||
| David Johnson | 4.9% | ||
|
RA Capital Management, L.P.
13G/A
Amendment 3
|
9.9% |
2/17/2026
Event 12/31/2025
|
|
| RA Capital Management, L.P. | 9.9% | ||
| Peter Kolchinsky | 9.9% | ||
| Rajeev Shah | 9.9% | ||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||
|
Balyasny Asset Management L.P.
13G/A
Amendment 1
|
2.4% |
2/17/2026
Event 12/31/2025
|
|
| Balyasny Asset Management L.P. | 2.4% | ||
| Bam GP LLC | 2.4% | ||
| Balyasny Asset Management Holdings LP | 2.4% | ||
| Dames GP LLC | 2.4% | ||
| Dmitry Balyasny | 2.4% | ||
|
Millennium Management LLC
13G
|
4.8% |
2/17/2026
Event 2/10/2026
|
|
| Millennium Management LLC | 4.8% | ||
| Millennium Group Management LLC | 4.8% | ||
| Israel A. Englander | 4.8% | ||
| OrbiMed Advisors LLC 13G/A Amendment 2 | 6.4% |
2/17/2026
Event 12/31/2025
|
|
|
Biotechnology Value Fund L P
13G/A
Amendment 3
|
10.0% |
2/17/2026
Event 12/31/2025
|
|
| Biotechnology Value Fund L P | 6.8% | ||
| BVF I GP LLC | 6.8% | ||
| Biotechnology Value Fund II LP | 2.7% | ||
| BVF II GP LLC | 2.7% | ||
| Biotechnology Value Trading Fund OS LP | 0.5% | ||
| BVF Partners OS Ltd. | 0.5% | ||
| BVF GP Holdings LLC | 9.4% | ||
| BVF Partners L P/IL | 10.0% | ||
| BVF Inc/IL | 10.0% | ||
| Lampert Mark N | 10.0% | ||
|
Point72 Asset Management, L.P.
13G/A
Amendment 2
|
3.5% |
2/17/2026
Event 12/31/2025
|
|
| Point72 Asset Management, L.P. | 3.5% | ||
| Point72 Capital Advisors, Inc. | 3.5% | ||
| Steven A. Cohen | 3.5% | ||
|
Millennium Management LLC
13G
|
4.9% |
2/10/2026
Event 2/3/2026
|
|
| Millennium Management LLC | 4.9% | ||
| Millennium Group Management LLC | 4.9% | ||
| Israel A. Englander | 4.9% | ||
|
SilverArc Capital Management, LLC
13G
|
2.8% |
2/10/2026
Event 12/31/2025
|
|
| SilverArc Capital Management, LLC | 2.8% | ||
| Devesh Gandhi | 2.8% | ||
|
Millennium Management LLC
13G
|
4.9% |
2/3/2026
Event 1/28/2026
|
|
| Millennium Management LLC | 4.9% | ||
| Millennium Group Management LLC | 4.9% | ||
| Israel A. Englander | 4.9% | ||
| Vanguard Group Inc 13G/A Amendment 1 | 4.4% |
1/30/2026
Event 12/31/2025
|
|
|
Affinity Asset Advisors, LLC
13G/A
Amendment 2
|
5.7% |
1/29/2026
Event 1/22/2026
|
|
| Affinity Asset Advisors, LLC | 5.7% | ||
| Michael Cho | 5.7% | ||
|
RA Capital Management, L.P.
13G/A
Amendment 2
|
9.9% |
11/14/2025
Event 9/30/2025
|
|
| RA Capital Management, L.P. | 9.9% | ||
| Peter Kolchinsky | 9.9% | ||
| Rajeev Shah | 9.9% | ||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||
|
Ikarian Capital, LLC
13G/A
Amendment 2
|
3.8% |
11/14/2025
Event 9/30/2025
|
|
| Ikarian Capital, LLC | 3.8% | ||
| Neil Shahrestani | 3.8% | ||
|
Balyasny Asset Management L.P.
13G
|
6.2% |
11/14/2025
Event 9/30/2025
|
|
| Balyasny Asset Management L.P. | 6.2% | ||
| Bam GP LLC | 6.2% | ||
| Balyasny Asset Management Holdings LP | 6.2% | ||
| Dames GP LLC | 6.2% | ||
| Dmitry Balyasny | 6.2% | ||
|
Deep Track Capital, LP
13G/A
Amendment 1
|
0% |
11/14/2025
Event 9/30/2025
|
|
| Deep Track Capital, LP | 0% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 0% | ||
| David Kroin | 0% | ||
|
Nantahala Capital Management, LLC
13G/A
Amendment 1
|
9.4% |
11/14/2025
Event 9/30/2025
|
|
| Nantahala Capital Management, LLC | 9.4% | ||
| Wilmot B. Harkey | 9.4% | ||
| Daniel Mack | 9.4% | ||
|
SilverArc Capital Management, LLC
13G
|
5.5% |
11/14/2025
Event 9/30/2025
|
|
| SilverArc Capital Management, LLC | 5.5% | ||
| Devesh Gandhi | 5.5% | ||
|
Biotechnology Value Fund L P
13G/A
Amendment 2
|
10.0% |
11/14/2025
Event 9/30/2025
|
|
| Biotechnology Value Fund L P | 5.5% | ||
| BVF I GP LLC | 5.5% | ||
| Biotechnology Value Fund II LP | 4.0% | ||
| BVF II GP LLC | 4.0% | ||
| Biotechnology Value Trading Fund OS LP | 0.3% | ||
| BVF Partners OS Ltd. | 0.3% | ||
| BVF GP Holdings LLC | 9.5% | ||
| BVF Partners L P/IL | 10.0% | ||
| BVF Inc/IL | 10.0% | ||
| Lampert Mark N | 10.0% | ||
|
Point72 Asset Management, L.P.
13G/A
Amendment 1
|
8.0% |
11/14/2025
Event 9/30/2025
|
|
| Point72 Asset Management, L.P. | 8.0% | ||
| Point72 Capital Advisors, Inc. | 8.0% | ||
| Steven A. Cohen | 8.0% | ||
|
Caligan Partners LP
13G
|
6.3% |
11/14/2025
Event 9/30/2025
|
|
| Caligan Partners LP | 6.3% | ||
| David Johnson | 6.3% | ||
|
Affinity Asset Advisors, LLC
13G/A
Amendment 1
|
7.7% |
11/13/2025
Event 9/30/2025
|
|
| Affinity Healthcare Fund, LP | 7.7% | ||
| Affinity Asset Advisors, LLC | 7.7% | ||
| Vanguard Group Inc 13G | 5.3% |
10/30/2025
Event 9/30/2025
|
|
| Patrick J. Crutcher 13G/A Amendment 2 | 4.2% |
8/27/2025
Event 8/6/2025
|
|
|
OrbiMed Advisors LLC
13G/A
Amendment 1
|
8.9% |
8/14/2025
Event 6/30/2025
|
|
| OrbiMed Advisors LLC | 8.9% | ||
| OrbiMed Capital GP IX LLC | 6.0% | ||
|
Point72 Asset Management, L.P.
13G
|
5.4% |
8/5/2025
Event 8/4/2025
|
|
| Point72 Asset Management, L.P. | 5.4% | ||
| Point72 Capital Advisors, Inc. | 5.4% | ||
| Steven A. Cohen | 5.4% | ||
|
RA Capital Management, L.P.
13G/A
Amendment 1
|
9.9% |
5/15/2025
Event 3/31/2025
|
|
| RA Capital Management, L.P. | 9.9% | ||
| Peter Kolchinsky | 9.9% | ||
| Rajeev Shah | 9.9% | ||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||
|
Nantahala Capital Management, LLC
13G
|
8.4% |
5/15/2025
Event 3/31/2025
|
|
| Nantahala Capital Management, LLC | 8.4% | ||
| Wilmot B. Harkey | 8.4% | ||
| Daniel Mack | 8.4% | ||
|
Ikarian Capital, LLC
13G/A
Amendment 1
|
10.0% |
5/15/2025
Event 3/31/2025
|
|
| Ikarian Capital, LLC | 10.0% | ||
| Neil Shahrestani | 10.0% | ||
|
Biotechnology Value Fund L P
13G/A
Amendment 1
|
10.0% |
2/14/2025
Event 12/31/2024
|
|
| Biotechnology Value Fund L P | 5.3% | ||
| BVF I GP LLC | 5.3% | ||
| Biotechnology Value Fund II LP | 4.2% | ||
| BVF II GP LLC | 4.2% | ||
| Biotechnology Value Trading Fund OS LP | 0.4% | ||
| BVF Partners OS Ltd. | 0.4% | ||
| BVF GP Holdings LLC | 9.5% | ||
| BVF Partners L P/IL | 10.0% | ||
| BVF Inc/IL | 10.0% | ||
| Lampert Mark N | 10.0% | ||
|
Affinity Asset Advisors, LLC
13G
|
5.3% |
12/31/2024
Event 12/23/2024
|
|
| Affinity Healthcare Fund, LP | 5.3% | ||
| Affinity Asset Advisors, LLC | 5.3% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 4 | 265 | $4.06 k |
| 2026 Q2 | 135 | 72.6 M | $1.34 B |
| 2026 Q1 | 110 | 31.2 M | $466 M |
| 2025 Q4 | 93 | 19.9 M | $361 M |
| 2025 Q3 | 72 | 15.3 M | $195 M |
| 2025 Q2 | 37 | 7.84 M | $39.1 M |
| 2025 Q1 | 35 | 8.26 M | $66.1 M |
| 2024 Q4 | 34 | 7.53 M | $56.0 M |
| 2024 Q3 | 31 | 6.66 M | $63.2 M |
| 2024 Q2 | 24 | 771 k | $9.62 M |
| 2024 Q1 | 22 | 87.6 k | $1.90 M |
| 2023 Q4 | 15 | 23.0 k | $210 k |